Fulvestrant Injection, Solution
Product Images NDC 63323-715

18 FDA label images from Fresenius Kabi Usa, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 63323-715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ful04 0007 01)

Figure 1 (Ful04 0007 01)
An instructional line drawing showing a hand holding a syringe with a vial attached. The illustration depicts a twisting motion, likely indicating how to attach or detach the vial from the syringe, relevant to preparing Fulvestrant 50 mg/mL injection for intramuscular use.*
FDA Label Image

Figure 2 (Ful04 0007 02)

Figure 2 (Ful04 0007 02)
An instructional illustration showing hands holding a syringe and vial, likely demonstrating the preparation or drawing of Fulvestrant 50 mg/mL injection solution for intramuscular administration. The image focuses on proper handling techniques of the injection components.*
FDA Label Image

Figure 3 (Ful04 0007 03)

Figure 3 (Ful04 0007 03)
An instructional diagram showing an injection syringe connected to a vial, depicting the preparation or administration setup for Fulvestrant injection solution. The diagram includes a close-up inset of the syringe needle or vial connection, illustrating the method for drawing up or delivering the medication intramuscularly.*
FDA Label Image

Figure 4 (Ful04 0007 04)

Figure 4 (Ful04 0007 04)
An illustration depicting a hand holding a syringe with the needle cap being removed, likely representing preparation for an intramuscular injection.*
FDA Label Image

Structural Formula (Ful04 0007 05)

Structural Formula (Ful04 0007 05)
Chemical structure of Fulvestrant, showing its steroid backbone with hydroxyl groups and a side chain containing sulfur and fluorinated groups.*
FDA Label Image

Figure 6 (Ful04 0007 06)

Figure 6 (Ful04 0007 06)
A Kaplan-Meier survival curve chart comparing progression-free survival over time (in months) for patients treated with Fulvestrant 250 mg and 500 mg. The y-axis shows the proportion of patients progression-free, and the x-axis shows time up to 45 months. A table below the graph displays the number of patients at risk over time for each dosage group.*
FDA Label Image

Figure 7 (Ful04 0007 07)

Figure 7 (Ful04 0007 07)
A line chart showing the proportion of patients alive over time in months for two groups receiving Fulvestrant at doses of 500 mg and 250 mg. The x-axis indicates time in months up to 80, and the y-axis shows the proportion of patients alive from 0 to 1. The chart includes patient numbers at risk for each time point and notes that tick marks represent censored observations. A statistical note indicates no significant difference due to lack of adjustments for multiplicity.*
FDA Label Image

Figure 8 (Ful04 0007 08)

Figure 8 (Ful04 0007 08)
A Kaplan-Meier survival curve showing the probability of progression-free survival (PFS) over time in months from randomization for two treatments: Fulvestrant 500 mg and Anastrozole 1 mg. The x-axis represents time in months, and the y-axis shows the probability of PFS. Patient numbers at risk are listed below the graph for both treatments at various time points.*
FDA Label Image

Figure 9 (Ful04 0007 09)

Figure 9 (Ful04 0007 09)
A Kaplan-Meier survival curve showing progression-free survival probability over time in months for two groups: palbociclib plus fulvestrant (solid line) and placebo plus fulvestrant (dashed line). The graph includes numbers of patients at risk along the time axis and defines abbreviations for fulvestrant, palbociclib, and placebo.*
FDA Label Image

Figure 10 (Ful04 0007 10)

Figure 10 (Ful04 0007 10)
A Kaplan-Meier curve graph showing overall survival probability (%) over time in months for two groups: fulvestrant plus palbociclib and fulvestrant plus placebo. The graph includes the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 11 (Ful04 0007 11)

Figure 11 (Ful04 0007 11)
A Kaplan-Meier plot showing progression-free survival probability (%) over time in months. The chart compares two groups: Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo, with lines depicting survival probabilities and censored observations. Below the plot, a table lists the number of patients at risk over time for each group.*
FDA Label Image

Figure 12 (Ful04 0007 12)

Figure 12 (Ful04 0007 12)
A Kaplan-Meier survival probability graph showing survival rates over time in months, comparing patients treated with Fulvestrant plus Abemaciclib against those treated with Fulvestrant plus Placebo. The chart includes censored observations and a patient risk table for each group at various time points up to 57 months.*
FDA Label Image

Figure 13 (Ful04 0007 13)

Figure 13 (Ful04 0007 13)
A Kaplan-Meier survival curve chart showing event-free probability (%) over time in months. The chart compares two groups: Fulvestrant plus Ribociclib (N=484) and Fulvestrant plus Placebo (N=242), with censoring times indicated. The survival probability declines over 26 months, with the Fulvestrant plus Ribociclib group maintaining higher event-free probability throughout the study period. Patient numbers at risk are tabulated below the time axis.*
FDA Label Image

Figure 14 (Ful04 0007 14)

Figure 14 (Ful04 0007 14)
A Kaplan-Meier survival curve comparing event-free probability (%) over time (months) between Fulvestrant with Ribociclib (N=484) and Fulvestrant with Placebo (N=242). The chart includes censoring times marked with symbols and a table below showing the number of patients still at risk at various time points up to 26 months.*
FDA Label Image

Fresenius Kabi Logo (Ful04 0007 15)

FDA Label Image

Fresenius Kabi Logo (Ful04 0007 16)

FDA Label Image

Principal Display Panel – Fulvestrant Injection 250 mg Per 5 mL Syringe Carton Panel (Ful04 0007 17)

Principal Display Panel – Fulvestrant Injection 250 mg Per 5 mL Syringe Carton Panel (Ful04 0007 17)
Packaging label for Fulvestrant Injection 250 mg per 5 mL (50 mg per mL) by Fresenius Kabi USA, LLC. The carton contains two pre-filled syringes, each with 250 mg in 5 mL for a total dose of 500 mg. The product is for intramuscular injection only. The label includes dosage instructions, storage conditions, and a barcode.*
FDA Label Image

Principal Display Panel – Fulvestrant Injection 250 mg Per 5 mL Syringe Label (Ful04 0007 18)

Principal Display Panel – Fulvestrant Injection 250 mg Per 5 mL Syringe Label (Ful04 0007 18)
Label for Fulvestrant Injection, 250 mg per 5 mL (50 mg per mL) solution for intramuscular use. The label states it is a single-dose pre-filled syringe containing 5 mL. It is manufactured for Fresenius Kabi USA, LLC in Lake Zurich, IL, made in Austria. The label includes dosage and administration instructions along with a barcode and NDC 63323-715-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.